SCHEMBL19973528

SCHEMBL19973528

COC(=O)c1ccccc1OCCC(=O)O

nearest known ligand 0.66

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.66
KMT2A Q03164 4/20 0.58
MEN1 O00255 3/20 0.58
GAA P10253 1/20 0.58
NPSR1 Q6W5P4 2/20 0.57
HSP90AA1 P07900 2/20 0.57
MAPT P10636 2/20 0.57
HTT P42858 1/20 0.57
KDM4E B2RXH2 2/20 0.55
SLC6A3 Q01959 1/20 0.55
HIF1A Q16665 1/20 0.53
ALDH1A1 P00352 6/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
CYP1A2 P05177 1/20 0.53
CYP2C9 P11712 1/20 0.53
HPGD P15428 1/20 0.53
CYP2C19 P33261 1/20 0.53
PTK2B Q14289 1/20 0.50
TSHR P16473 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25365376 0.92 NPSR1 (0.63) LMNAKMT2AMEN1GAANPSR1
SCHEMBL4947321 0.87 HSP90AA1 (0.57) LMNAKMT2AMEN1GAANPSR1
Benzene SCHEMBL28006415 0.84 MAPT (0.60) LMNAKMT2AMEN1GAANPSR1
SCHEMBL2454087 0.84 ALDH1A1 (0.71) LMNAKMT2AMEN1GAANPSR1
SCHEMBL6280141 0.83 HSP90AA1 (0.59) LMNAKMT2AMEN1GAANPSR1
SCHEMBL2555648 0.83 LMNA (0.70) LMNAKMT2AMEN1NPSR1MAPT
SCHEMBL385973 0.83 HSP90AA1 (0.59) LMNAKMT2AMEN1GAANPSR1
SCHEMBL536427 0.83 MAPT (0.59) LMNAKMT2AMEN1GAANPSR1
SCHEMBL1280991 0.83 POLB (0.64) LMNAKMT2AMEN1GAANPSR1
SCHEMBL5507668 0.83 ALDH1A1 (0.71) LMNAKMT2AMEN1NPSR1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11001564-B2 Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same ARBUTUS BIOPHARMA CORPORATION (CA) 2021-05-11 US disclosed
US-11001564-B2 Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same ARBUTUS BIOPHARMA CORPORATION (CA) 2021-05-11 US disclosed
US-20190225593-A1 SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA CORP (CA) 2019-07-25 US disclosed
US-20190225593-A1 SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA CORP (CA) 2019-07-25 US disclosed
WO-2018052967-A1 SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA, INC. (US) 2018-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190225593-A1 SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME CBX8, HAVCR2, HCCS LMNA 477/4885KMT2A 155/4885MEN1 1933/4885
US-11001564-B2 Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same CBX8, HAVCR2, HCCS LMNA 477/4885KMT2A 155/4885MEN1 1933/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.